Education
About Us
Working with TipRanks
Follow Us
Thermo Fisher (TMO)
NYSE:TMO
TMO Stock Chart & Stats
$474.39
$0.83(0.15%)
At close: 4:00 PM EST
$474.39
$0.83(0.15%)
Day’s Range― - ―
52-Week Range$385.46 - $643.99
Previous CloseN/A
Volume471.20K
Average Volume (3M)2.25M
Market Cap
$176.23B
Enterprise Value$208.61B
Total Cash (Recent Filing)$10.11B
Total Debt (Recent Filing)$40.85B
Price to Earnings (P/E)32.3
Beta0.71
Next Earnings
Apr 29, 2026EPS Estimate
5.25Next Dividend Ex-DateN/A
Dividend Yield0.3%
Share Statistics
EPS (TTM)6.57
Shares Outstanding371,484,250
10 Day Avg. Volume2,354,567
30 Day Avg. Volume2,246,983
Financial Highlights & Ratios
PEG Ratio4.51
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue4.68
Enterprise Value/Gross Profit11.87
Enterprise Value/Ebitda18.17
Forecast
1Y Price Target
$671.33Price Target Upside41.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)24.57
Revenue Forecast (FY)$46.85B
Bulls Say, Bears Say
Bulls Say
CDMO DemandConstrained global sterile fill-finish capacity is sustaining strong demand for the company's CDMO services, supporting revenue growth as biopharma firms seek contract manufacturing.
Integrated Accelerator OfferingsAn integrated Accelerator business that combines CDMO and clinical CRO capabilities aims to accelerate project execution and shorten time-to-market for new drugs, which could generate meaningful new orders.
Strategic Acquisitions And Capacity ExpansionStrategic acquisitions expanding U.S. production capacity are positioned to strengthen global leadership in bioproduction and capture onshore demand amid geopolitical uncertainty.
Bears Say
Guidance And End-market OutlookReduced growth guidance that landed below analyst expectations signals a cautious end-market outlook and may limit near-term upside if demand does not reaccelerate.
Leadership Change And Guidance UncertaintyA change in the company's chief financial officer introduces uncertainty into the guidance process and may complicate investor visibility on upcoming financial results.
Margin PressureAdjusted operating and gross margins coming in slightly below expectations point to margin pressure and potential cost challenges that could weigh on profitability.
Thermo Fisher News
TMO FAQ
What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest stock price was $385.46 and its highest was $643.99 in the past 12 months.
What is Thermo Fisher’s market cap?
Thermo Fisher’s market cap is $176.23B.
When is Thermo Fisher’s upcoming earnings report date?
Thermo Fisher’s upcoming earnings report date is Apr 29, 2026 which is in 36 days.
How were Thermo Fisher’s earnings last quarter?
Thermo Fisher released its earnings results on Jan 29, 2026. The company reported $6.57 earnings per share for the quarter, beating the consensus estimate of $6.449 by $0.121.
Is Thermo Fisher overvalued?
According to Wall Street analysts Thermo Fisher’s price is currently Undervalued.
Does Thermo Fisher pay dividends?
Thermo Fisher pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 0.3%. See more information on Thermo Fisher dividends here
What is Thermo Fisher’s EPS estimate?
Thermo Fisher’s EPS estimate is 5.25.
How many shares outstanding does Thermo Fisher have?
Thermo Fisher has 371,484,250 shares outstanding.
What happened to Thermo Fisher’s price movement after its last earnings report?
Thermo Fisher reported an EPS of $6.57 in its last earnings report, beating expectations of $6.449. Following the earnings report the stock price went down -2.608%.
Which hedge fund is a major shareholder of Thermo Fisher?
Currently, no hedge funds are holding shares in TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$671.33 (41.51% Upside)
$671.33 (41.51% Upside)
Blogger Sentiment
Bullish
TMO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 677.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.19%
12-Months-Change
Fundamentals
Return on Equity
13.15%
Trailing 12-Months
Asset Growth
13.38%
Trailing 12-Months
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
TMO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: solid top-line growth, strong adjusted EPS growth, robust cash generation, aggressive strategic M&A and product innovation, and constructive 2026 guidance (3%–4% organic growth and 6%–8% EPS growth). Headwinds from tariffs, foreign exchange volatility, China and academic/government softness, margin pressure in Analytical Instruments, and elevated leverage represent notable near-term risks but appear manageable given the company’s PPI-driven productivity, capital deployment discipline, and pipeline of innovations and strategic deals.View all TMO earnings summariesTMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics
TMO Stock 12 Month Forecast
Average Price Target
$671.33
▲(41.51% Upside)
Technical Analysis
Ownership Overview
0.13% Insiders
25.05% Mutual Funds
35.82% Other Institutional Investors
19.81% Public Companies and Individual Investors